Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset

IF 4.4 2区 医学 Q1 CLINICAL NEUROLOGY Annals of Clinical and Translational Neurology Pub Date : 2023-08-17 DOI:10.1002/acn3.51875
Heike Jacobi, Tamara Schaprian, Tanja Schmitz-Hübsch, Matthias Schmid, Thomas Klockgether, the EUROSCA and RISCA Study Groups
{"title":"Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset","authors":"Heike Jacobi,&nbsp;Tamara Schaprian,&nbsp;Tanja Schmitz-Hübsch,&nbsp;Matthias Schmid,&nbsp;Thomas Klockgether,&nbsp;the EUROSCA and RISCA Study Groups","doi":"10.1002/acn3.51875","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Our aim was to study the evolution of ataxia and neurological symptoms before and after ataxia onset in the most common spinocerebellar ataxias (SCAs), SCA1, SCA2, SCA3 and SCA6. We therefore jointly analysed the data of the EUROSCA and RISCA studies, which recruited ataxic and non-ataxic mutation carriers.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We used mixed effect models to analyse the evolution of Scale for the Rating and Assessment of Ataxia (SARA) scores, SCA Functional Index (SCAFI) and Inventory of Non-Ataxia Signs (INAS) counts. We applied multivariable modelling to identify factors associated with SARA progression. In the time interval 5 years prior to and after ataxia onset, we calculated sensitivity to change ratios (SCS) of SARA, SCAFI and INAS.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>2740 visits of 677 participants were analysed. All measures showed non-linear progression that was best fitted by linear mixed models with linear, quadratic and cubic time effects. <i>R</i><sup>2</sup> values indicating quality of the fit ranged from 0.70 to 0.97. CAG repeat was associated with faster progression in SCA1, SCA2 and SCA3, but not SCA6. 5 years prior to and after ataxia onset, SARA had the highest SCS of all measures with a mean of 1.21 (95% CI: 1.20, 1.21) in SCA1, 0.94 (0.93, 0.94) in SCA2 and 1.23 (1.22, 1.23) in SCA3.</p>\n </section>\n \n <section>\n \n <h3> Interpretation</h3>\n \n <p>Our data have important implications for the understanding of disease progression in SCA1, SCA2, SCA3 and SCA6 across the lifespan. Furthermore, our study provides information for the design of interventional trials, especially in pre-ataxic mutation carriers close to ataxia onset and patients in early disease stages.</p>\n </section>\n </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":"10 10","pages":"1833-1843"},"PeriodicalIF":4.4000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.51875","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acn3.51875","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Our aim was to study the evolution of ataxia and neurological symptoms before and after ataxia onset in the most common spinocerebellar ataxias (SCAs), SCA1, SCA2, SCA3 and SCA6. We therefore jointly analysed the data of the EUROSCA and RISCA studies, which recruited ataxic and non-ataxic mutation carriers.

Methods

We used mixed effect models to analyse the evolution of Scale for the Rating and Assessment of Ataxia (SARA) scores, SCA Functional Index (SCAFI) and Inventory of Non-Ataxia Signs (INAS) counts. We applied multivariable modelling to identify factors associated with SARA progression. In the time interval 5 years prior to and after ataxia onset, we calculated sensitivity to change ratios (SCS) of SARA, SCAFI and INAS.

Results

2740 visits of 677 participants were analysed. All measures showed non-linear progression that was best fitted by linear mixed models with linear, quadratic and cubic time effects. R2 values indicating quality of the fit ranged from 0.70 to 0.97. CAG repeat was associated with faster progression in SCA1, SCA2 and SCA3, but not SCA6. 5 years prior to and after ataxia onset, SARA had the highest SCS of all measures with a mean of 1.21 (95% CI: 1.20, 1.21) in SCA1, 0.94 (0.93, 0.94) in SCA2 and 1.23 (1.22, 1.23) in SCA3.

Interpretation

Our data have important implications for the understanding of disease progression in SCA1, SCA2, SCA3 and SCA6 across the lifespan. Furthermore, our study provides information for the design of interventional trials, especially in pre-ataxic mutation carriers close to ataxia onset and patients in early disease stages.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脊髓小脑共济失调1型、2型、3型和6型在共济失调发作前后的疾病进展
目的研究最常见的脊髓小脑共济失调(SCAs)、SCA1、SCA2、SCA3和SCA6在共济失调发作前后共济失调和神经系统症状的演变。因此,我们联合分析了EUROSCA和RISCA研究的数据,这些研究招募了共济失调和非共济失调突变携带者。方法采用混合效应模型分析共济失调评定量表(SARA)评分、SCA功能指数(SCAFI)和非共济失调症状量表(INAS)计数的演变。我们应用多变量建模来确定与严重急性呼吸系统综合征进展相关的因素。在时间间隔5 在共济失调发作前后几年,我们计算了严重急性呼吸系统综合征、SCAFI和INAS的敏感性变化率(SCS)。结果对677名参与者的2740次访问进行了分析。所有测量都显示出非线性进展,具有线性、二次和三次时间效应的线性混合模型最适合这种进展。表示拟合质量的R2值在0.70到0.97之间。CAG重复与SCA1、SCA2和SCA3的更快进展有关,但与SCA6无关。5. 共济失调发作前后几年,严重急性呼吸系统综合征的SCS在所有指标中最高,SCA1的平均值为1.21(95%CI:1.20,1.21),SCA2为0.94(0.93,0.94),SCA3为1.23(1.22,1.23)。解释我们的数据对理解SCA1、SCA2、SCA3和SCA6在整个生命周期中的疾病进展具有重要意义。此外,我们的研究为干预试验的设计提供了信息,特别是在接近共济失调发作的共济失调前突变携带者和疾病早期患者中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology Medicine-Neurology (clinical)
CiteScore
9.10
自引率
1.90%
发文量
218
审稿时长
8 weeks
期刊介绍: Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.
期刊最新文献
Brain lesion characteristics in Chinese multiple sclerosis patients: A 7-T MRI cohort study. Efficacy and safety of DL-3-N-butylphthalide in the treatment of ischemic poststroke aphasia: A randomized clinical trial. Optical genome mapping: Unraveling complex variations and enabling precise diagnosis in dystrophinopathy. Issue Information Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1